심방세동 시장 : 시장 규모, 점유율 , 성장률, 산업 분석, 유형별, 용도별, 지역별 고찰 및 예측(2026-2034년)

Growth Factors of atrial fibrillation Market

The global atrial fibrillation market is experiencing steady growth, driven by the rising prevalence of cardiovascular disorders, increasing geriatric population, and continuous advancements in pharmacological therapies. Atrial fibrillation (Afib) is a cardiac arrhythmia characterized by irregular and often rapid heart rhythm, which significantly increases the risk of stroke, heart failure, and other cardiovascular complications. The condition is commonly associated with hypertension, cardiomyopathy, obesity, smoking, and advancing age, making it a growing public health concern worldwide.

In 2025, the global atrial fibrillation market size was valued at USD 17.24 billion. The market is projected to grow to USD 17.99 billion in 2026 and further reach USD 25.75 billion by 2034, exhibiting a CAGR of 4.59% from 2026 to 2034. The consistent expansion of the market reflects the increasing demand for effective long-term management therapies and improved patient access to treatment options.

Market Drivers

The rising burden of cardiovascular diseases is one of the primary factors driving market growth. According to the World Health Organization (WHO), 1.28 billion adults globally were suffering from hypertension in 2023, a key risk factor for atrial fibrillation. Structural and functional changes in the heart caused by hypertension significantly increase the likelihood of arrhythmias.

Additionally, the rapidly growing geriatric population is contributing to the rising prevalence of Afib. As per the United Nations 2023 report, the global population aged 65 years and above is projected to reach 1.6 billion by 2050, leading to higher demand for atrial fibrillation therapies. Increasing awareness, early diagnosis, and expanding access to healthcare services in developing regions are further supporting market growth.

Market Trends

A major trend shaping the market is the increasing focus on novel drug development, particularly monoclonal antibodies and Factor XI/XIa inhibitors. Key pharmaceutical players are investing heavily in innovative therapies aimed at reducing bleeding risks while maintaining anticoagulant efficacy. For instance, Anthos Therapeutics is developing abelacimab, a fully human monoclonal antibody designed to provide hemostasis-sparing anticoagulation.

Regulatory bodies are also supporting innovation by granting fast-track approvals and special designations, enabling faster clinical development and market entry of novel therapies. This trend is expected to significantly improve treatment outcomes and expand therapeutic options during the forecast period.

COVID-19 Impact

The atrial fibrillation market experienced slow growth during the COVID-19 pandemic, mainly due to supply chain disruptions, temporary clinic closures, and reduced elective procedures. According to a 2022 publication in the Journal of Clinical Medicine, there was a notable decline in catheter ablation and left atrial appendage occlusion procedures during the pandemic.

However, pharmacotherapy remained the preferred treatment approach, supporting steady drug demand. Post-pandemic recovery led to a rebound in diagnoses and treatment initiation, allowing the market to return to normal growth levels.

Restraining Factors

Despite positive growth prospects, the market faces challenges from rising product recalls and the availability of alternative treatment approaches. Product recalls due to manufacturing defects, labeling errors, and quality concerns can negatively impact brand trust and patient adherence. For example, recalls of drugs such as dofetilide and digoxin in 2023 raised safety concerns and temporarily affected market confidence, potentially shifting patient preference toward non-pharmacological interventions.

Segmentation Analysis

By drug class, the market is segmented into anticoagulants and antiarrhythmic drugs. The anticoagulants segment dominated the market, accounting for 78.92% share in 2026, driven by strong clinical guidelines and widespread adoption of direct oral anticoagulants (DOACs).

By route of administration, the oral segment led the market with an 84.98% share in 2026, owing to ease of use, better patient compliance, and a wide range of orally available drugs.

By distribution channel, retail pharmacies dominated with a 48.03% share in 2026, supported by consumer convenience, expanding pharmacy networks, and cost advantages.

Regional Insights

North America dominated the atrial fibrillation market in 2025, accounting for 38.33% market share and valued at USD 6.61 billion. The region benefits from a high disease prevalence, strong regulatory support, and a large elderly population. The U.S. market is projected to reach USD 6.14 billion by 2026.

Europe held the second-largest share, driven by increasing cardiovascular disease prevalence and strong R&D investments. Asia Pacific is projected to witness the fastest growth due to rising awareness, expanding healthcare infrastructure, and a rapidly aging population. By 2026, Japan, China, and India are projected to reach USD 0.69 billion, USD 0.89 billion, and USD 0.64 billion, respectively.

Competitive Landscape

The global market is semi-consolidated, with key players such as Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi, Pfizer, and Johnson & Johnson. These companies focus on product innovation, clinical trials, geographic expansion, and strategic collaborations to strengthen their market positions.

Conclusion

The global atrial fibrillation market is poised for steady growth, supported by the rising prevalence of cardiovascular disorders, an expanding geriatric population, and continuous advancements in drug development. Valued at USD 17.24 billion in 2025, the market is expected to grow to USD 25.75 billion by 2034. While challenges such as product recalls and alternative treatment options persist, ongoing innovation, supportive regulatory frameworks, and increasing global awareness are expected to sustain market expansion and create long-term growth opportunities.

Segmentation By Drug Class

• Anticoagulants
• Antiarrhythmic Drugs

By Route of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region

• North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
• 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
• 4.3. New Product Launches by Key Players
• 4.4. Impact of COVID-19 on Atrial Fibrillation Market

5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Anticoagulants
  • 5.1.2. Anti-arrhythmic Drugs
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Intravenous
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Online Pharmacies
  • 5.3.3. Retail Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Anticoagulants
  • 6.1.2. Anti-arrhythmic Drugs
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Intravenous
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Online Pharmacies
  • 6.3.3. Retail Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Drug Class
  • 6.4.2. Canada
    • 6.4.2.1. By Drug Class

7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Anticoagulants
  • 7.1.2. Anti-arrhythmic Drugs
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Intravenous
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Online Pharmacies
  • 7.3.3. Retail Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Drug Class
  • 7.4.2. U.K.
    • 7.4.2.1. By Drug Class
  • 7.4.3. France
    • 7.4.3.1. By Drug Class
  • 7.4.4. Spain
    • 7.4.4.1. By Drug Class
  • 7.4.5. Italy
    • 7.4.5.1. By Drug Class
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Drug Class
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Drug Class

8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Anticoagulants
  • 8.1.2. Anti-arrhythmic Drugs
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Intravenous
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Online Pharmacies
  • 8.3.3. Retail Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Drug Class
  • 8.4.2. China
    • 8.4.2.1. By Drug Class
  • 8.4.3. India
    • 8.4.3.1. By Drug Class
  • 8.4.4. Australia
    • 8.4.4.1. By Drug Class
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Drug Class
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Drug Class

9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Anticoagulants
  • 9.1.2. Anti-arrhythmic Drugs
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Intravenous
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Online Pharmacies
  • 9.3.3. Retail Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Drug Class
  • 9.4.2. Mexico
    • 9.4.2.1. By Drug Class
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Drug Class

10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Anticoagulants
  • 10.1.2. Anti-arrhythmic Drugs
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Intravenous
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Online Pharmacies
  • 10.3.3. Retail Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Drug Class
  • 10.4.2. South Africa
    • 10.4.2.1. By Drug Class
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Drug Class

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Bristol-Myers Squibb Company
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Sanofi
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Eisai Co., Ltd.
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Johnson & Johnson
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Daiichi Sankyo, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Par Pharmaceutical
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Bayer AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Pfizer Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)